A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease

ClinicalTrials.gov Identifier: NCT05821153, Registered April 20 2023, Retrospectively registered, https://classic.clinicaltrials.gov/ct2/show/NCT05821153 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40035-023-00387-5.

Detalles Bibliográficos
Autores principales: Faridar, Alireza, Eid, Abdulmunaim M., Thome, Aaron D., Zhao, Weihua, Beers, David R., Pascual, Maria B., Nakawah, Mohammad O., Roman, Gustavo C., Davis, Charles S., Grundman, Michael, Masdeu, Joseph C., Appel, Stanley H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652426/
https://www.ncbi.nlm.nih.gov/pubmed/37968718
http://dx.doi.org/10.1186/s40035-023-00387-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652426/
https://www.ncbi.nlm.nih.gov/pubmed/37968718
http://dx.doi.org/10.1186/s40035-023-00387-5

Ejemplares similares